Catalyst Pharmaceuticals, Inc.

  • Earnings Score
  • Moat Score
  • Market Cap $2.74B
  • PE 19
  • Debt $NaN
  • Cash $442.33M
  • EV $NaN
  • FCF $224.02M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$142.80M
EBIT$188.79M
ROE22%
ROA24%
FCF$224.02M
Equity$660.94M
Growth Stability100%
PE19.21
PEG1.13
PB4.15
P/FCF12.24
P/S5.96
Price/Cash0.16
Net Margins31%
Gross Margins86%
Op. Margins41%
Earnings CAGR7%
Sales Growth YoY25%
Sales Growth QoQ5%
Sales CAGR29%
FCF CAGR5%
Equity CAGR33%
Earnings Stability0.13
Earnings Growth YoY-243%
Earnings Growth QoQ8%
Earnings CAGR 5Y17%
Sales CAGR 5Y41%
FCF CAGR 5Y35%
Equity CAGR 5Y46%
Earnings CAGR 3Y61%
Sales CAGR 3Y61%
FCF CAGR 3Y55%
Equity CAGR 3Y53%
Market Cap$2.74B
Revenue$460.48M
Assets$772.01M
Cash$442.33M
Shares Outstanding117.98M
Earnings Score8%
Moat Score97%
Working Capital433.6M
Current Ratio5.11
Shares Growth 3y6%
Equity Growth QoQ9%
Equity Growth YoY90%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

SEC Filings

Direct access to Catalyst Pharmaceuticals, Inc. (CPRX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Catalyst Pharmaceuticals, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Catalyst Pharmaceuticals, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 7%
Stability 13%
loading chart...

Catalyst Pharmaceuticals, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Catalyst Pharmaceuticals, Inc..

= $3.1B
012345678910TV
fcf$224M$235M$246M$257M$270M$283M$296M$310M$325M$340M$356M$3.6B
DCF$213M$203M$193M$184M$175M$167M$159M$151M$144M$137M$1.4B
Value$3.1B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins-----7K%31%63%28%39%18%31%
ROA--34%-43%-22%-56%30%22%22%28%20%24%
ROE--36%-46%-23%-67%36%44%19%28%18%22%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF-----------
Debt over Equity-----------
Growth Stability-------100%100%100%100%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-----20K%16%18%52%86%41%
Earnings YoY growth-30%-11%2%85%-194%135%-47%110%-14%17%
Equity YoY growth-57%-29%106%-37%73%94%22%45%29%46%
FCF YoY growth-39%0%---234%30%32%95%24%35%